Zanolimumab: Difference between revisions
Content deleted Content added
No edit summary |
Anypodetos (talk | contribs) m →References: Resolve template redirect, replaced: {{humanmonoclonals}} → {{Monoclonals for immune system}} using AWB |
||
| Line 33: | Line 33: | ||
{{immunosuppressants}} |
{{immunosuppressants}} |
||
{{Monoclonals for immune system}} |
|||
{{humanmonoclonals}} |
|||
Revision as of 08:10, 19 December 2010
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | CD4 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| Chemical and physical data | |
| Molar mass | 147 kDa |
Zanolimumab (expected trade name HuMax-CD4[1]) is a human monoclonal antibody and an immunosuppressive drug. It is being developed for the treatment of rheumatoid arthritis, psoriasis, melanoma [2], cutaneous and peripheral T-cell lymphoma.[3][4]
References
- ^ Genmab initiates Phase II Study with HuMax-CD4
- ^ http://www.tenxbiopharma.com/development.shtml
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Zanolimumab, American Medical Association.
- ^ Clinical trial number NCT00042406 for "Trial With HuMax-CD4 in Patients With Rheumatoid Arthritis Failing Treatment With Methotrexate and a TNF-Alpha Blocker" at ClinicalTrials.gov
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |